FDA accepts Atara’s resubmitted tab-cel application and sets March 2027 review deadline
The U.S. Food and Drug Administration accepted Atara Biotherapeutics’ resubmitted application for tabelecleucel, or tab-cel, to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The agency set March 31, 2027, as its target decision date under PDUFA. If authorized, the therapy could become the first U.S. treatment for this condition, while Pierre Fabre’s commercialization arrangement would make Atara eligible for a $31.0M milestone and royalties.
Why it matters
The FDA acceptance establishes a defined regulatory catalyst for Atara, but approval is still conditional on the agency’s review. A favorable decision would also activate the reported milestone and potential royalty economics under the Pierre Fabre agreement.
Key facts
- 1The FDA accepted the Class 2 resubmission and set March 31, 2027, as its PDUFA target action date. stocktitan.net
- 2Pierre Fabre Pharmaceuticals submitted the application for patients aged two years and older with EBV-positive post-transplant lymphoproliferative disease who had received at least one prior therapy. investing.com
- 3Atara could receive a $31.0M milestone payment if the treatment is approved. tradingview.com
- 4Tab-cel has FDA Breakthrough Therapy and orphan-drug designations for the cited EBV-related indications. investing.com
Open questions
- FDA approval is not assured, and the agency could delay its action or issue another complete response letter.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.